ICON Is Collaborating with Practice Fusion, Inc. to Advance Health Research
June 27 2018 - 7:00AM
Business Wire
ICON plc, (NASDAQ: ICLR) a global provider of drug
development services to the pharmaceutical, biotechnology and
medical device industries, today announced that it is working with
Practice Fusion to leverage active patient data in support of
health research.
Practice Fusion, Inc., an Allscripts company, is an industry
leading cloud-based ambulatory electronic health record (EHR)
platform in the US, supporting more than 20,000 medical practices
to deliver better care to over five million patients monthly.
Practice Fusion offers connectivity solutions and services that can
help make healthcare management better for everyone—including
clinical labs, pharmacies, imaging centres, health systems and
other US healthcare ecosystem stakeholders. These connected
partners utilize the Practice Fusion platform to help coordinate
care, and help develop innovative programs to improve outcomes,
reduce costs and enhance the patient experience.
“The collaboration between ICON and Practice Fusion explores
innovative uses of data collected directly through the Practice
Fusion platform to facilitate health research. Focus areas for
potential collaboration include: the ability to rapidly develop
‘Real-world’ Registries; the use of the EHR platform to streamline
data collection for late phase studies and post-market research
programs; as well as the real time identification of ‘active’
patients for engagement in health research programs”, commented
Ramita Tandon, EVP ICON Commercialization and Outcomes.
Working with “Real” patient data, connected healthcare
providers, and data collected directly through an EHR system
represents an order of magnitude improvement over second-hand
sources that the FDA has cited as filled with discrepancies and
which is not timely.
The relationship with Practice Fusion is another example of
ICON’s leadership in applying targeted technology to help customers
reduce the time and cost of their development programs through more
accurate patient identification, research though real-world patient
records and faster patient recruitment.
“The use of EHR systems offers a significant differentiator of
second-hand data resources for more efficient retrospective and
hybrid studies in addition to selection of sites and patient
recruitment” continued Ramita Tandon, EVP ICON Commercialization
and Outcomes.
“Working with ICON will enable Practice Fusion network
physicians to potentially improve the quality and value of patient
care by accelerating research and actively contributing to
Real-World Evidence which may be critical for developing novel
treatments and communicating treatment value”, said Tom Langan,
CEO, Payer & Life Sciences, Allscripts.
About ICON plcICON plc is a global provider of outsourced
drug development and commercialisation services to pharmaceutical,
biotechnology, medical device, and government and public health
organisations. The company specializes in the strategic
development, management and analysis of programs that support
clinical development from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 97 locations in 38 countries and has approximately
13,380 employees.
Further information is available at www.iconplc.com
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180627005554/en/
ICON Media ContactOlivia PimentaWeber Shandwick44-207 067
0557OPimenta@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Sep 2023 to Sep 2024